Erlotinib is a kinase inhibitor indicated for:
The treatment of patients with metastatic non-small cell lung cancer(NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.
First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
|Don't take the drug without consulting a qualified doctor or physician.
|Follow the doctor's advice
|Delivery & Returns